Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 17;30(1):305.
doi: 10.1186/s40001-025-02563-x.

Short- and mid-term outcomes after redo surgical valve replacement

Pardis Sadeghi  1 , Ali Hosseinsabet  1 , Reza Mohseni-Badalabadi  2 , Arash Jalali  3   4 , Ahmad Vakili-Basir  3   4 , Mina Pashang  5 , Negar Omidi  1 , Jamshid Bagheri  6 , Mohammadjavad Mehrabanian  7
Affiliations

Short- and mid-term outcomes after redo surgical valve replacement

Pardis Sadeghi et al. Eur J Med Res. .

Abstract

Background: While previous studies have indicated comparable outcomes for redo surgical valve replacement (SVR) and primary SVR, there is limited information regarding the long-term follow-up of these patients. Providing prognostic data on redo SVR is crucial for enhancing decision-making and medical care, as well as for identifying low-risk subsets of patients eligible for redo SVR. This study aimed to evaluate the short- and mid-term outcomes of patients who underwent their first and second redo SVR of a previously replaced valve.

Methods: We included 118 consecutive patients with a history of first or second redo SVR. The participants had a mean age of 57.5 ± 14.4 years, with 71 (60%) being female. The median follow-up period was 69 months. Clinical, intraoperative, and laboratory data were analyzed to assess all-cause mortality, major adverse events (MAE), and a composite of prosthetic valve thrombosis, embolic events, and major hemorrhage (TEH), along with their predictors. Bayesian model averaging was used for statistical analysis.

Results: The 30-day mortality rate was 11 patients (9.3%). Chronic kidney disease was identified as an independent predictor of 30-day mortality. The overall survival rates at one and five years were 86% (95% CI 80% to 93%) and 76% (95% CI 68% to 85%), respectively. Dyslipidemia, a history of major bleeding, chronic kidney disease, stroke, and transvalvular leakage in biological prostheses were all associated with all-cause mortality as independent predictors. The TEH-free survival rates at one and five years were 91% (95% CI 86% to 97%) and 79% (95% CI 71% to 88%), respectively. Diabetes, sex, a history of percutaneous coronary intervention, and baseline functional capacity were identified as independent predictors for the occurrence of TEH. The MAE-free survival rates at one and five years were 82% (95% CI 73% to 92%) and 61% (95% CI 49% to 75%), respectively. Hypertension and baseline functional class were independent predictors of MAE occurrence. The type and anatomical position of the valve were not predictors of mortality, THE, and MAE.

Conclusions: Our study demonstrated acceptable short- and mid-term outcomes for redo SVR, especially in patients without significant risk factors. Several potential predictors of adverse outcomes were identified.

Keywords: Mortality; Prognosis; Prosthetic valve; Redo surgery; Valve replacement.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: The research proposal was approved by the institutional review board (IR.TUMS.THC.REC.1401.005) following the 1964 Declaration of Helsinki and its later amendments. Written informed consent was obtained from the study population. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
The images illustrate A the actuarial overall survival; B a composite of valve thrombosis, embolic events, and hemorrhage-free survival after the first and second redo surgical valve replacement operations; and C major adverse event-free survival rates. MAE; Major adverse event, TEB; Valve thrombosis, embolic events, and bleeding (hemorrhage)
Fig. 2
Fig. 2
The images present forest plots of multivariable analysis of study outcomes. FC; Functional class, PCI; Percutaneous coronary intervention
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Coffey S, Roberts-Thomson R, Brown A, Carapetis J, Chen M, Enriquez-Sarano M, Zühlke L, Prendergast BD. Global epidemiology of valvular heart disease. Nat Rev Cardiol. 2021;18(12):853–64. 10.1038/s41569-021-00570-z. - PubMed
    1. Santangelo G, Bursi F, Faggiano A, Moscardelli S, Simeoli PS, Guazzi M, Lorusso R, Carugo S, Faggiano P. The global burden of valvular heart disease: from clinical epidemiology to management. J Clin Med. 2023;12(6):2178. 10.3390/jcm12062178. - PMC - PubMed
    1. Writing Committee Members, Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O’Gara PT, Rigolin VH, Sundt TM 3rd, Thompson A, Toly C, ACC/AHA Joint Committee Members, O’Gara PT, Beckman JA, Levine GN, Al-Khatib SM, Armbruster A, Birtcher KK, Ciggaroa J, Deswal A, Dixon DL, Fleisher LA, de Las Fuentes L, Gentile F, Goldberger ZD, Gorenek B, Haynes N, Hernandez AF, Hlatky MA, Joglar JA, Jones WS, Marine JE, Mark D, Palaniappan L, Piano MR, Spatz ES, Tamis-Holland J, Wijeysundera DN, Woo YJ. ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Thorac Cardiovasc Surg. 2021;162(2):e183–353. 10.1016/j.jtcvs.2021.04.002. - PubMed
    1. Serban A, Dadarlat-Pop A, Achim A, Gavan D, Pepine D, Rancea R, Tomoaia R. Diagnosis of left-sided mechanical prosthetic valve thrombosis: a pictorial review. J Pers Med. 2023;13(6):967. 10.3390/jpm13060967. - PMC - PubMed
    1. Aluru JS, Barsouk A, Saginala K, Rawla P, Barsouk A. Valvular heart disease epidemiology. Med Sci (Basel). 2022;10(2):32. 10.3390/medsci10020032. - PMC - PubMed

LinkOut - more resources